Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for Relapsed or Refractory Hematopoietic and Lymphoid Malignancies
NCT03312205Phase 2Unknown
- Sponsor
- Senlang Bio
- Start
- Aug 2017
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in leukemia, lymphoma and multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoint: Tumor load up to 24 months. Status: unknown.
02
Conditions
leukemialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT03312205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312205.